These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31821228)

  • 21. Synthetic cannabinoids and potential reproductive consequences.
    Sun X; Dey SK
    Life Sci; 2014 Feb; 97(1):72-7. PubMed ID: 23827241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of COMT (rs4680), CNR2 (rs2501432), CNR2 (rs2229579), UCP2 (rs659366), and IL-17 (rs763780) gene variants in synthetic cannabinoid use disorder patients.
    Pehlivan S; Aytac HM; Kurnaz S; Pehlivan M; Cetinay Aydin P
    J Addict Dis; 2020; 38(4):495-505. PubMed ID: 32662357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychosis and substance abuse: cause, effect or coincidence?
    Lawrie SM; Hutchison JK; Sweeney SR; Fernando MR; McAdam CA; Monsour MR; Campbell TJ; MacLeod CM
    Scott Med J; 1995 Dec; 40(6):174-6. PubMed ID: 8693334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists.
    Benford DM; Caplan JP
    Psychosomatics; 2011; 52(3):295. PubMed ID: 21565605
    [No Abstract]   [Full Text] [Related]  

  • 25. Human Laboratory Studies on Cannabinoids and Psychosis.
    Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M
    Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
    Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
    Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
    Ricci V; Ceci F; Di Carlo F; Di Muzio I; Ciavoni L; Santangelo M; Di Salvo G; Pettorruso M; Martinotti G; Maina G
    Psychiatry Res; 2023 Feb; 320():115053. PubMed ID: 36682093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences between substance-induced psychotic disorders and non-substance-induced psychotic disorders and diagnostic stability.
    Cambra Almerge J; Sánchez-Romero S; Arias Horcajadas F
    Adicciones; 2023 Jul; 35(2):95-106. PubMed ID: 36975062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Acute Psychosis after Consumption of Synthetic Cannabinoids].
    Mörkl S; Blesl C; Wurm WE; Tmava A
    Fortschr Neurol Psychiatr; 2016 Mar; 84(3):150-4. PubMed ID: 27029042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient.
    Peglow S; Buchner J; Briscoe G
    Am J Addict; 2012; 21(3):287-8. PubMed ID: 22494236
    [No Abstract]   [Full Text] [Related]  

  • 31. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.
    McQuade D; Hudson S; Dargan PI; Wood DM
    Eur J Clin Pharmacol; 2013 Mar; 69(3):373-6. PubMed ID: 22936123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary psychosis with comorbid drug abuse and drug-induced psychosis: Diagnostic and clinical evolution at follow up.
    Mauri MC; Di Pace C; Reggiori A; Paletta S; Colasanti A
    Asian J Psychiatr; 2017 Oct; 29():117-122. PubMed ID: 29061407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-hospital identification and post-recovery challenges of intoxication with synthetic cannabinoid containing legal high products such as 'Exodus Damnation'.
    Fitzpatrick D; O'Meara P; Cunningham A
    Scott Med J; 2016 Nov; 61(4):192-194. PubMed ID: 27688259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitrous Oxide Inhalant Use Disorder Preceding Symptoms Concerning for Primary Psychotic Illness.
    Roberts D; Farahmand P; Wolkin A
    Am J Addict; 2020 Nov; 29(6):525-527. PubMed ID: 32333625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis.
    Caton CL; Hasin DS; Shrout PE; Drake RE; Dominguez B; First MB; Samet S; Schanzer B
    Br J Psychiatry; 2007 Feb; 190():105-11. PubMed ID: 17267925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.
    Murrie B; Lappin J; Large M; Sara G
    Schizophr Bull; 2020 Apr; 46(3):505-516. PubMed ID: 31618428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune system: a possible nexus between cannabinoids and psychosis.
    Suárez-Pinilla P; López-Gil J; Crespo-Facorro B
    Brain Behav Immun; 2014 Aug; 40():269-82. PubMed ID: 24509089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis.
    McGuire PK; Jones P; Harvey I; Williams M; McGuffin P; Murray RM
    Schizophr Res; 1995 May; 15(3):277-81. PubMed ID: 7632625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic Cannabinoid Receptor Agonists: a heterogeneous class of novel psychoactive substance with emerging risk of psychosis.
    Whiting D
    Evid Based Ment Health; 2015 Nov; 18(4):110. PubMed ID: 26363038
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.